Romosozumab plus alendronate vs alendronate alone was associated with improved lumbar spine BMD among postmenopausal women with T2D and osteoporosis. Romosozumab followed by alendronate treatment ...

Alendronate has been shown to increase bone mineral density (BMD) and decrease fracture risk in postmenopausal women with osteoporosis, but the need for long-term treatment is unclear, especially ...

In re Fosamax (Alendronate Sodium), No. 11-5304, 08-08; U.S. District Court (DNJ); opinion by Pisano, U.S.D.J.; filed June 27, 2013. DDS No. 36-7-xxxx [17 pp.] Fosamax (Alendronate Sodium) is approved ...

Alendronate sodium 70 mg with colecalciferol micrograms and calcium carbonate 1. Prior to treatment, osteoporosis must be confirmed by the finding of low bone mass of at least 2 standard deviations ...

In this analysis, 3 bisphosphonates (alendronate, pamidronate, and zoledronic acid) and 1 RANK ligand inhibitor (denosumab) were evaluated for their effectiveness at preventing osteoclasts from ...

April 14, 2005 -- The U.S. Food and Drug Administration (FDA) has approved mometasone furoate inhalation powder for the maintenance treatment of asthma as prophylactic therapy in patients aged 12 ...

Please provide your email address to receive an email when new articles are posted on . Denosumab as a first-line osteoporosis therapy is linked to lower fracture risks than alendronate among ...

Statin pills for patient with high cholesterol Decrease in bone mass is common in the first 6 to 12 months after kidney transplantation. Long-term use of alendronate, a bisphosphonate, may slow bone ...

Credit: Shutterstock. Treatment with Prolia was associated with greater reductions in the overall relative risk across various fracture types. Treatment with denosumab (Prolia ®) was associated with ...

Compared with alendronate, teriparatide was associated with significantly greater pain reduction and better quality of life among postmenopausal women with osteoporosis. Teriparatide has a favorable ...

We have written before about the Supreme Court’s impossibility preemption decision, Merck Sharpe & Dohme Corp. v. Albrecht, 139 S. Ct. 1668 (2019) (Albrecht) (here, here, here, and here), highlighting ...